MRI in CLN2 disease patients: Subtle features that support an early diagnosis

dc.authorid0000-0003-1513-6149
dc.contributor.authorAydın, Kürşad
dc.contributor.authorHavalı, Cengiz
dc.contributor.authorKartal, Ayşe
dc.contributor.authorSerdaroğlu, Ayşe
dc.contributor.authorHaspolat, Şenay
dc.date.accessioned2020-11-05T09:28:32Z
dc.date.available2020-11-05T09:28:32Z
dc.date.issued2020
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractNeuronal ceroid lipofuscinosis type 2 (CLN2) disease is a rare, paediatric-onset, neurodegenerative disorder characterised in its early stages by language delay, seizures and loss of motor function. It is rapidly progressive and ultimately results in the premature death of patients. We aim to highlight common magnetic resonance imaging (MRI) features seen in early CLN2 disease and increase disease awareness among clinicians in order to facilitate early diagnosis and treatment of patients with disease-modifying enzyme replacement therapy.We obtained MRI scans from 12 Turkish children with CLN2 disease, at symptom onset or time of diagnosis, and at various times during disease progression. Patient details including age at onset of symptoms, age at diagnosis and clinical presentation were collected. MRIs were analysed to identify common features present in patients with CLN2 disease.The median diagnostic delay in this cohort was 2 years, highlighting the need for increased disease awareness among clinicians. Key MRI features suggestive of CLN2 disease that were identified included cerebellar atrophy in 11 patients, linear hyperintensity of central white matter in 10 patients, cerebral atrophy in 8 patients and thinning of the corpus callosum in 6 patients. Thalamic hypointensity was seen in 1 patient and may also indicate CLN2 disease.It is important to consider the presenting symptoms alongside clinical test results in order to support early diagnosis of CLN2 disease. Clinical suspicion of CLN2 disease accompanied by the detection of any of the above-mentioned features on MRI should encourage healthcare professionals to test for CLN2 disease.
dc.description.sponsorshipBioMarin Pharmaceutical Inc.en_US
dc.identifier.citationAydın, K., Havalı, C., Kartal, A., Serdaroğlu, A. ve Haspolat, Ş. (2020). MRI in CLN2 disease patients: Subtle features that support an early diagnosis. European Journal of Paediatric Neurology, 28, 228-236. https://dx.doi.org/10.1016/j.ejpn.2020.07.009
dc.identifier.doi10.1016/j.ejpn.2020.07.009
dc.identifier.endpage236
dc.identifier.issn1090-3798
dc.identifier.issn1532-2130
dc.identifier.scopusqualityQ1
dc.identifier.startpage228
dc.identifier.urihttps://dx.doi.org/10.1016/j.ejpn.2020.07.009
dc.identifier.urihttps://hdl.handle.net/20.500.12511/6000
dc.identifier.volume28
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Ltd
dc.relation.ispartofEuropean Journal of Paediatric Neurologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCLN2
dc.subjectPediatric
dc.subjectMRI
dc.subjectCerebellum
dc.subjectAtrophy
dc.subjectHyperintensity
dc.titleMRI in CLN2 disease patients: Subtle features that support an early diagnosis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Aydin, Kursad-2020.pdf
Boyut:
3.14 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: